A Phase 3 interventional study of Semaglutide Pen Injector and Placebo in Diabetes Mellitus, Type 1, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by University of Colorado, Denver · Phase 3, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing semaglutide in Diabetes Mellitus, Type 1 — 11 open to participants now, 12 under way, 7 of them phase 3. Semaglutide · Diabetes Mellitus, Type 1.
Among the 16 studies testing semaglutide in Diabetes Mellitus, Type 1, this one is the 8th largest by planned enrollment, is one of 3 that started in 2023, is one of 4 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 7th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →11 of the 16 studies testing semaglutide in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 40–90
Vanderbilt University Medical Center · Sites in United States
Ages 12–50
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 8 · Phase 4 1
First in 2019; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 60 across the 16 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver: 10 open now, 13 under way, 1 of them phase 3. Of 43 finished, 19 (44%) have results posted.
Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, this one is the 14th largest by planned enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 3, reaches primary completion later than 8 of the 12 other live ones, and was the 49th registered.
University of Colorado, Denver’s Diabetes Mellitus, Type 1 studies by the year they started, since 1993.
4 of the studies testing semaglutide in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
| NCT05819138Phase 3University of Colorado, DenverType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | 2027-10-01 |
| NCT06338553Vanderbilt University Medical CenterGLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab | 2027-03 |
| NCT05822609University of WashingtonTrial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing semaglutide in Diabetes Mellitus, Type 1, from their registry updates:
Among University of Colorado, Denver’s 58 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 0.25 mg once weekly semaglutide injection for 4 weeks. Participants will receive 0.50 mg once weekly semaglutide injection for 4 weeks. Participants will receive 1.0 mg once weekly semaglutide injection for 6 months.
Drug: Semaglutide Pen Injector
Participants will receive 0.25 mg once weekly placebo injection for 4 weeks. Participants will receive 0.50 mg once weekly placebo injection for 4 weeks. Participants will receive 1.0 mg once weekly placebo injection for 6 months.
Drug: Placebo
Semaglutide injection
Also known as: Ozempic
Semaglutide placebo injection
Change in Ascending Aortic Pulse Wave Velocity (AA PWV)
AA PWV is a measure of central arterial stiffness. A lower value indicates a better outcome.
Time frame: Baseline, month 8
Change in Carotid and Femoral Artery Pulse Wave Velocity (CF-PWV)
CF-PWV is a measure of peripheral arterial stiffness. A lower value indicates a better outcome.
Time frame: Baseline, month 8
Change in Carotid and Radial Artery Pulse Wave Velocity (CR-PWV)
CR-PWV is a measure of peripheral arterial stiffness. A lower value indicates a better outcome.
Time frame: Baseline, month 8
Change in Insulin Sensitivity
Insulin Sensitivity is a measure of how well the body responds insulin. A higher value indicates a better outcome; a lower value indicates a worse outcome.
Time frame: Baseline, month 8
Change in Renal Vascular Resistance (RVR)
RVR is a measure of mean arterial pressure to renal blood flow. A higher value indicates a worse outcome.
Time frame: Baseline, month 8
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Oct 2027, 51 months after the start.
Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 51 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
University of Colorado, Denver →